Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $225.00 short call and a strike $230.00 long call offers a potential 12.61% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $225.00 by expiration. The full premium credit of $0.56 would be kept by the premium seller. The risk of $4.44 would be incurred if the stock rose above the $230.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 29.09 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Eaton Vance Exits Celgene, Trims Amgen Position
Tue, 04 Feb 2020 19:32:23 +0000
Health care-focused fund's largest sales of the 4th quarter Continue reading…
Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal
Tue, 04 Feb 2020 16:50:04 +0000
Teva (TEVA) posts positive results from two phase II/III studies on Ajovy for treating patients with chronic and episodic migraine in Japan.
Analysts Forecast Huge Upsides for Aimmune, Biohaven
Tue, 04 Feb 2020 15:22:36 +0000
Optimism surrounds these companies’ launch of drugs in 2020 Continue reading…
Amgen Stock Rises 3%
Tue, 04 Feb 2020 14:03:00 +0000
Investing.com – Amgen (NASDAQ:AMGN) Stock rose by 3.02% to trade at $223.28 by 14:01 (19:01 GMT) on Tuesday on the NASDAQ exchange.
The Biggest Biotech Is Facing Profitability Worries — Is It Time To Buy Amgen Stock?
Mon, 03 Feb 2020 15:00:53 +0000
Amgen stock is facing concerns that its adjusted earnings will slide in 2020. Is it time to buy shares of the biotech company?
Also on Market Tamer…
Follow Us on Facebook